The BC-CfE’s BOOST (Best practices in Oral Opioid agoniSt Therapy) Collaborative hosted its fourth learning session of the year-long project, drawing collaborators from across BC
Fifty-three year old Vancouver resident Sage Rinaldo lived with hepatitis C for many years before working up the courage to seek treatment. Rinaldo credits a community health nurse in the Downtown Eastside who gained her trust and helped her successfully treat her hepatitis C with a new anti-viral treatment. Now, Rinaldo is giving back by taking part in a long-term follow up study focussed on reinfection prevention. The Per-SVR study is aiming to better understand if, how and when hepatitis C reinfection may occur.
The lifetime experiences of gay and bisexual men differ across generations. Some studies have proposed that these varied histories can impact attitudes towards sex and alter sexual behaviours. The BC-CfE’s Momentum Health Study-based on a cohort of gay, bisexual and other men who have sex with men (gbMSM) in the Greater Vancouver area-set out to investigate this concept.
A new fact sheet explains the made-in-BC Treatment as Prevention®¨ strategy and how it works.
The COAST study observes health outcomes of people living with HIV, as compared with the general population.
The teams participating in the BC-CfE’s Provincial BOOST Collaborative met in June for its third learning session, and is now approaching the halfway point for the quality improvement project aiming to improve engagement in treatment for opioid use disorder.
The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below
